TW201922706A - 含氮雜芳基化合物及該化合物之醫藥用途 - Google Patents
含氮雜芳基化合物及該化合物之醫藥用途 Download PDFInfo
- Publication number
- TW201922706A TW201922706A TW107134941A TW107134941A TW201922706A TW 201922706 A TW201922706 A TW 201922706A TW 107134941 A TW107134941 A TW 107134941A TW 107134941 A TW107134941 A TW 107134941A TW 201922706 A TW201922706 A TW 201922706A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- group
- acceptable salt
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017194005 | 2017-10-04 | ||
| JP2017-194005 | 2017-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201922706A true TW201922706A (zh) | 2019-06-16 |
Family
ID=65994698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107134941A TW201922706A (zh) | 2017-10-04 | 2018-10-03 | 含氮雜芳基化合物及該化合物之醫藥用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10752596B2 (enExample) |
| EP (1) | EP3693358B1 (enExample) |
| JP (1) | JP7125882B2 (enExample) |
| KR (1) | KR20200064101A (enExample) |
| CN (1) | CN111148735B (enExample) |
| AR (1) | AR113270A1 (enExample) |
| AU (1) | AU2018345221A1 (enExample) |
| BR (1) | BR112020004857A2 (enExample) |
| CA (1) | CA3074989A1 (enExample) |
| CL (1) | CL2020000898A1 (enExample) |
| CO (1) | CO2020003977A2 (enExample) |
| IL (1) | IL273573A (enExample) |
| MX (1) | MX2020003816A (enExample) |
| PE (1) | PE20200846A1 (enExample) |
| PH (1) | PH12020550403A1 (enExample) |
| RU (1) | RU2020115045A (enExample) |
| SG (1) | SG11202003005PA (enExample) |
| TW (1) | TW201922706A (enExample) |
| WO (1) | WO2019069973A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156698B (zh) * | 2019-06-06 | 2020-10-13 | 沈阳海诺威医药科技有限公司 | 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途 |
| CN113181206B (zh) * | 2021-04-30 | 2023-07-14 | 青岛大学 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
| IL313713A (en) * | 2022-01-07 | 2024-08-01 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of glut9 for treatment of disease |
| CN114805192B (zh) * | 2022-03-30 | 2023-05-23 | 华南理工大学 | 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用 |
| WO2024167952A1 (en) * | 2023-02-08 | 2024-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oxidatively cleavable organophosphate drugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| SK283261B6 (sk) * | 1996-07-18 | 2003-04-01 | Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. | Substituované pyridíny, farmaceutický prostriedok s ich obsahom a ich použitie |
| BR9910122A (pt) * | 1998-04-10 | 2001-10-16 | Japan Tobacco Inc | Compostos amidina |
| WO2005013907A2 (en) * | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| JP2007176933A (ja) * | 2005-11-29 | 2007-07-12 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5162827B2 (ja) | 2005-12-27 | 2013-03-13 | ぺんてる株式会社 | 鉛筆芯の製造方法 |
| JP5330990B2 (ja) | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| JP2009016193A (ja) * | 2007-07-05 | 2009-01-22 | Daihen Corp | 電気機器用樹脂ブッシング |
| DK2455381T5 (en) * | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| CN104306363B (zh) * | 2014-10-31 | 2017-06-06 | 南京葆赫生物技术有限公司 | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 |
-
2018
- 2018-10-03 PE PE2020000529A patent/PE20200846A1/es unknown
- 2018-10-03 BR BR112020004857-7A patent/BR112020004857A2/pt not_active Application Discontinuation
- 2018-10-03 US US16/150,989 patent/US10752596B2/en active Active
- 2018-10-03 CN CN201880064738.0A patent/CN111148735B/zh active Active
- 2018-10-03 TW TW107134941A patent/TW201922706A/zh unknown
- 2018-10-03 WO PCT/JP2018/037007 patent/WO2019069973A1/ja not_active Ceased
- 2018-10-03 AU AU2018345221A patent/AU2018345221A1/en not_active Abandoned
- 2018-10-03 EP EP18864398.5A patent/EP3693358B1/en active Active
- 2018-10-03 AR ARP180102853A patent/AR113270A1/es unknown
- 2018-10-03 CA CA3074989A patent/CA3074989A1/en not_active Abandoned
- 2018-10-03 MX MX2020003816A patent/MX2020003816A/es unknown
- 2018-10-03 RU RU2020115045A patent/RU2020115045A/ru unknown
- 2018-10-03 KR KR1020207012149A patent/KR20200064101A/ko not_active Withdrawn
- 2018-10-03 SG SG11202003005PA patent/SG11202003005PA/en unknown
- 2018-10-03 JP JP2018188038A patent/JP7125882B2/ja active Active
-
2020
- 2020-03-24 IL IL273573A patent/IL273573A/en unknown
- 2020-03-31 CO CONC2020/0003977A patent/CO2020003977A2/es unknown
- 2020-04-02 CL CL2020000898A patent/CL2020000898A1/es unknown
- 2020-04-06 PH PH12020550403A patent/PH12020550403A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190152926A1 (en) | 2019-05-23 |
| SG11202003005PA (en) | 2020-04-29 |
| WO2019069973A1 (ja) | 2019-04-11 |
| IL273573A (en) | 2020-05-31 |
| MX2020003816A (es) | 2020-08-13 |
| CN111148735A (zh) | 2020-05-12 |
| AU2018345221A1 (en) | 2020-05-07 |
| CA3074989A1 (en) | 2019-04-11 |
| CN111148735B (zh) | 2023-08-08 |
| PH12020550403A1 (en) | 2021-02-15 |
| BR112020004857A2 (pt) | 2020-09-15 |
| CO2020003977A2 (es) | 2020-04-24 |
| EP3693358B1 (en) | 2023-02-22 |
| KR20200064101A (ko) | 2020-06-05 |
| EP3693358A1 (en) | 2020-08-12 |
| PE20200846A1 (es) | 2020-08-18 |
| US10752596B2 (en) | 2020-08-25 |
| JP7125882B2 (ja) | 2022-08-25 |
| AR113270A1 (es) | 2020-03-11 |
| CL2020000898A1 (es) | 2020-08-14 |
| EP3693358A4 (en) | 2021-06-02 |
| JP2019065009A (ja) | 2019-04-25 |
| RU2020115045A (ru) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI423962B (zh) | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 | |
| TW201922706A (zh) | 含氮雜芳基化合物及該化合物之醫藥用途 | |
| JP6569792B2 (ja) | ハロゲン置換へテロ環化合物 | |
| KR102474640B1 (ko) | 카르복실산 화합물, 이의 제조방법, 및 이의 용도 | |
| CN107108478B (zh) | Urat1抑制剂 | |
| JP2014507478A (ja) | 可溶性グアニル酸シクラーゼ活性化因子 | |
| TW201619146A (zh) | １－烷基－６－側氧基－１，６－二氫吡啶－３－基化合物及其用途 | |
| WO2021175283A1 (zh) | 新型ep4拮抗剂的合成及其在癌症和炎症中的用途 | |
| WO2006004030A1 (ja) | 組織因子産生抑制剤 | |
| US9902709B2 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| JP2021536484A (ja) | １，７−ナフチリジン系誘導体及びその製造方法並び用途 | |
| CN111499591A (zh) | RORγ调节剂 | |
| ES2965041T3 (es) | Composiciones para el tratamiento de la fibrosis pulmonar | |
| JP4749335B2 (ja) | イミダゾピリジン化合物 | |
| KR20130093068A (ko) | 치환 피리딘 화합물 | |
| TW202220961A (zh) | Ｐｈｄ抑制劑化合物、組成物及使用方法 | |
| CA2979407C (en) | Compositions for the treatment of kidney and/or liver disease | |
| HK40027595A (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| WO2022037601A1 (zh) | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 | |
| HK1241355A1 (en) | Urat1 inhibitor |